Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614947 · ClinicalTrials.gov registry record · NA
Impact of 60 Days Powdered Tart Cherry Supplementation on Metabolic Syndrome
A NA study of Metabolic Syndrome, sponsored by Ohio University.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05614947: Completed NA study of Metabolic Syndrome, sponsored by Ohio University.
NCT05614947 is a NA study of Metabolic Syndrome that has completed, run by Ohio University. The registered enrollment target is 25 participants, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05614947, a NA study of Metabolic Syndrome, has completed, sponsored by Ohio University.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Metabolic syndrome (MetSyn) is a growing health concern, with up to 25% of the worlds population having the syndrome. MetSyn is a primary risk factor for cardiovascular disease and type II diabetes development, and is independently associated with all-cause mortality, making it an important disease target. The primary treatment for MetSyn is exercise and weight loss, along with medically necessary treatment. Exercise, along with dietary changes such as increased fiber and polyphenol intake can positively impact many of the metabolic abnormalities seen with MetSyn. For example, polyphenols have been shown to decrease lipid concentration and improved glucose clearance as well as decreased oxidative stress and inflammation. Powdered tart cherry capsules, which contain the skin of the fruit, provides polysaccharides (fiber) that would likely act as a substrate for gut bacteria degradation, providing energy substrates and barrier integrity to the colonocytes and increasing the bioavailability of the polyphenols to other cells in the body. However there have been no long-term investigations into the use of powdered tart cherry supplements in MetSyn, therefore we aim to determine if 60 days tart cherry supplementation modify criteria for MetSyn in currently diagnosed individuals including body mass, waist circumference, blood pressure, blood lipid levels and blood glucose control.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Powdered tart cherry
Study Locations (1)
Ohio
- Ohio University Exercise Physiology Lab - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-04-06 |
| Est. Completion | 2025-07-25 |
| Phase | NA |
What the finished NCT05614947 record still lists
NCT05614947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Metabolic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05614947 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05614947 about?
NCT05614947 is a clinical study titled "Impact of 60 Days Powdered Tart Cherry Supplementation on Metabolic Syndrome". Metabolic syndrome (MetSyn) is a growing health concern, with up to 25% of the worlds population having the syndrome. MetSyn is a primary risk factor for cardiovascular disease and type II diabetes development, and is independently associated with all-cause mortality, making it an important disease ...
What is the current status of trial NCT05614947?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2022-04-06. Estimated completion is 2025-07-25.
What conditions does trial NCT05614947 study?
This clinical trial studies the following conditions: Metabolic Syndrome.
What interventions are being tested in trial NCT05614947?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Powdered tart cherry (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05614947?
This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05614947 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05614947's enrollment target sits among peer trials
25 84th of 102 higher than 18 of 102 other Metabolic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Animal and Plant Proteins and Glucose Metabolism
RECRUITING · NA
-
VR Stimulation of Exercise Response in Sedentary Humans
RECRUITING · NA
-
Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI